University of British Columbia, Dept. of Psychiatry
Welcome,         Profile    Billing    Logout  
 7 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Young, Allan
INTENSIFY SZ, NCT05958875: The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Recruiting
4
418
Europe
Clozapine, ATC code: N05AH02, Second-line Antipsychotics (treatment as usual)
Dr. Inge Winter, Universität Münster
Schizophrenia and Related Disorders, Early Treatment-Resistance
06/26
06/26
ELICE_BD, NCT02731612: Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients

Recruiting
3
150
Europe, Canada, Japan, US
lurasidone, Latuda, Placebo
Nazlin Walji
Bipolar Disorder
12/24
03/25
INTENSIFY MDD, NCT05973851: The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Recruiting
3
418
Europe
Esketamine Nasal Product, ATC code: N06AB10, Ketamine Hydrochloride, N01AX03, Esketamine hydrochloride, N015X14, Second-line Antidepressants
Dr. Inge Winter, Universität Münster
Major Depressive Disorder, Treatment Resistant Depression
06/26
06/26
INTENSIFY BD, NCT05973786: The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Recruiting
3
418
Europe
Escitalopram, ATC code: N06AB10, Sertraline, ATC code: N06AB06, Venlafaxine, ATC code: N06AX16, Lithium, ATC code: N05AN01, Valproate acid, ATC code: N03AG01, Quetiapine, ATC code: N05AH04
Dr. Inge Winter, Universität Münster
Bipolar Depression
06/26
06/26
GO-MARK, NCT04977674: Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine

Completed
1
27
Europe
Naltrexone, Placebo, Ketamine
King's College London
Depressive Disorder, Treatment-Resistant
02/23
02/23
NCT03633357: Imaging 5HT7 Antagonist Effects in Bipolar Disorder

Recruiting
N/A
68
Europe
JNJ-18038683, Placebo
King's College London
Bipolar Disorder
06/22
06/22
RHAPSODY, NCT04939818: Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders

Completed
N/A
172
Europe
Novoic Limited, King's College London
Alzheimer Disease, Mild Cognitive Impairment, Dementia With Lewy Bodies, Dementia, Vascular, Frontotemporal Dementia, Primary Progressive Aphasia, Parkinson Disease, Motor Neuron Disease, Major Depressive Disorder, Bipolar Disorder, Amyotrophic Lateral Sclerosis
09/22
09/22
PSY-PGx, NCT05656469: Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing As Usual in Psychiatric Disorders

Recruiting
N/A
2500
Europe, US, RoW
Personalised medication advice based on pharmacogenetic testing
Maastricht University Medical Center, Parnassia Psychiatric Institute, University of Belgrade, University of Bonn, Babes-Bolyai University, State University of New York - Upstate Medical University, Ludwig-Maximilians - University of Munich, King's College London, University of Barcelona
Mood Disorders, Anxiety Disorders, Psychotic Disorders
03/25
03/25
RESTORE-LIFE, NCT03320304: A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients with Difficult to Treat Depression.

Recruiting
N/A
500
Europe
Vagal Nerve Simulation (VNS) Therapy
LivaNova
Treatment Resistant Depression
12/26
12/28

Download Options